Spyre director-linked fund granted 8,026 options

Spyre Therapeutics, Inc. reported a routine insider equity award involving director Tomas Kiselak and Fairmount-affiliated funds.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. reported a routine insider equity award involving director Tomas Kiselak and Fairmount-affiliated funds. An option was granted covering 8,026 shares of common stock at an exercise price of $72.51 per share, expiring on May 27, 2036. The option vests in full on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, subject to Mr. Kiselak’s continued service. Under his arrangement with Fairmount Funds Management LLC, any net cash or stock from this option is for the benefit of Fairmount-managed investment vehicles, and Mr. Kiselak disclaims beneficial ownership except for his pecuniary interest.

Insider Trade Summary

Grant/Award: 8,026 shares

Grant/Award 1 txn

Insider Fairmount Funds Management LLC, Kiselak Tomas, Fairmount Healthcare Fund II L.P.

Role Director | Director | Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,026	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 8,026 contracts (Indirect, By Tomas Kiselak)

Footnotes (2)

1. F1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to Tomas Kiselak's continuous service to the Issuer through the applicable vesting date.
2. F2. Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

Key Figures

Option grant size: 8,026 shares Exercise price: $72.51 per share Options after grant: 8,026 options +2 more

5 metrics

Option grant size 8,026 shares Stock Option (Right to Buy) underlying common shares

Exercise price $72.51 per share Conversion or exercise price of granted options

Options after grant 8,026 options Total derivative securities following transaction

Expiration date May 27, 2036 Option expiration for this grant

Vesting date trigger May 27, 2027 Earlier of this date or 2027 annual meeting, subject to service

Key Terms

Stock Option (Right to Buy), beneficial ownership, pecuniary interest, derivative, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

beneficial ownership financial

"Mr. Kiselak therefore disclaims beneficial ownership of the option"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

continuous service financial

"subject to Tomas Kiselak's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Spyre Therapeutics (SYRE) Form 4 disclose about insider equity awards?

The Form 4 shows a grant of stock options covering 8,026 shares of Spyre Therapeutics common stock. These options were awarded in connection with director Tomas Kiselak’s service and are linked to investment vehicles managed by Fairmount Funds Management LLC.

How many Spyre Therapeutics (SYRE) shares are covered by the new stock option grant?

The stock option grant covers the right to purchase 8,026 shares of Spyre Therapeutics common stock. This entire amount becomes exercisable once the vesting conditions are satisfied, subject to continuous service requirements tied to director Tomas Kiselak.

What is the exercise price and term of the Spyre Therapeutics (SYRE) options granted?

The options have an exercise price of $72.51 per share and expire on May 27, 2036. This gives the holder a long-dated right to buy Spyre common stock at that fixed price if the options vest and are exercised.

When do the newly granted Spyre Therapeutics (SYRE) options vest?

The options vest and become fully exercisable on the earlier of May 27, 2027 or the 2027 annual meeting of stockholders. Vesting is conditioned on Tomas Kiselak’s continuous service to Spyre Therapeutics through the applicable vesting date.

Who effectively benefits from the Spyre Therapeutics (SYRE) option grant reported for Tomas Kiselak?

Under Kiselak’s arrangement with Fairmount Funds Management LLC, any net cash or stock from the option is for Fairmount-managed investment vehicles. He disclaims beneficial ownership of the option and underlying shares, except for his pecuniary interest in those funds.

Is the Spyre Therapeutics (SYRE) Form 4 transaction an open-market purchase or sale?

No, the filing reports a stock option grant classified as a derivative award, not an open-market trade. The transaction code is “A,” indicating a grant or award acquisition rather than a purchase or sale on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fairmount Funds Management LLC

(Last) (First) (Middle)

200 BARR HARBOR DRIVE

SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$72.51	05/27/2026		A		8,026		(1)	05/27/2036	Common Stock	8,026	$0	8,026	I	By Tomas Kiselak(2)

1. Name and Address of Reporting Person^*

Fairmount Funds Management LLC

(Last) (First) (Middle)

200 BARR HARBOR DRIVE

SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kiselak Tomas

(Last) (First) (Middle)

200 BARR HARBOR DRIVE

SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Fairmount Healthcare Fund II L.P.

(Last) (First) (Middle)

200 BARR HARBOR DRIVE

SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to Tomas Kiselak's continuous service to the Issuer through the applicable vesting date.

2. Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

Remarks:

The Adviser and Fairmount Healthcare Fund II L.P. may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is also a Managing Member of the Adviser.

	/s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P.	05/29/2026
	/s/ Tomas Kiselak	05/29/2026
	/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)